Enzalutamide vs Bicalutamide — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Androgen Receptor Inhibitor

Enzalutamide

Brand: Xtandi

First FDA approval: 2012-08-31

Androgen Receptor Inhibitor

Bicalutamide

Brand: CASODEX

First FDA approval: 1995-10-04

Lowest NADACAcquisition cost floor across all NDCs

—Per unit

$0.403Per unit

Average NADACAcross all dosage forms and strengths

—

$0.403Up to $0.403

Generic manufacturersActive ANDA holders — FDA Orange Book

00 total ANDAs filed

66 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$5.84BFull year

$10.9MFull year

Part D claims (CY24)Total fills, all strengths

433K75K beneficiaries

310K123K beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$13,470Per claim, all NDCs

$35Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

981Substantial friction

0Zero PA friction

Step therapy appliedPlan-NDC pairs requiring step therapy

0None

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

Generic availableFDA Orange Book

NoBrand-only

Yes6 manufacturers